Predicted to have several functions, including DNA-binding transcription factor activity, RNA polymerase II-specific; E-box binding activity; and protein homodimerization activity. Involved in several processes, including animal organ development; positive regulation of epithelial cell proliferation; and roof of mouth development. Localizes to nucleus. Biomarker of pulmonary hypertension. Human ortholog(s) of this gene implicated in Saethre-Chotzen syndrome; Sweeney-Cox syndrome; acrocephalosyndactylia; and craniosynostosis. Orthologous to human TWIST1 (twist family bHLH transcription factor 1); PARTICIPATES IN hypoxia inducible factor pathway; INTERACTS WITH 6-propyl-2-thiouracil; ammonium chloride; benzo[a]pyrene.
[sodium arsenite results in increased abundance of Arsenic] which affects the expression of TWIST1 protein, [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA
[sodium arsenite results in increased abundance of Arsenic] which affects the expression of TWIST1 protein, [sodium arsenite results in increased abundance of Arsenic] which results in increased expression of TWIST1 mRNA
cobaltous chloride results in increased expression of and affects the localization of TWIST1 protein, tetraethylenepentamine inhibits the reaction [cobaltous chloride results in increased expression of and affects the localization of TWIST1 protein]
CA9 mutant form inhibits the reaction [[Oxygen deficiency results in increased expression of CA9 mRNA] which results in increased expression of TWIST1 mRNA]
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein, TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
[[Gasoline co-treated with isobutyl alcohol] results in increased abundance of [Particulate Matter co-treated with Polycyclic Aromatic Hydrocarbons]] which results in decreased expression of TWIST1 mRNA
[NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of TWIST1 mRNA
[Methylnitrosourea co-treated with Testosterone] results in increased expression of TWIST1 mRNA, Quercetin inhibits the reaction [[Methylnitrosourea co-treated with Testosterone] results in increased expression of TWIST1 mRNA]
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein, TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]
[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of TWIST1 mRNA
[NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of TWIST1 mRNA
[NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of TWIST1 mRNA
pyrazolanthrone inhibits the reaction [thymoquinone results in decreased expression of TWIST1 protein], SB 203580 inhibits the reaction [thymoquinone results in decreased expression of TWIST1 protein]
[NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of TWIST1 mRNA
[NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-5-benzo1, 3dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-ylbenzamide] results in increased expression of TWIST1 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin